Autoimmune gastritis is a chronic inflammatory disorder in which the immune system targets components of the stomach—most classically the gastric parietal cells that produce hydrochloric acid and intrinsic factor. Intrinsic factor is essential for vitamin B12 absorption in the terminal ileum; therefore, progressive autoimmune damage can lead to autoimmune-mediated iron deficiency and pernicious anemia. Patients may experience upper gastrointestinal discomfort, early satiety, bloating, nausea, and dyspepsia, but the severity and pattern of symptoms vary widely. A commonly highlighted concept is the idea that the stomach is being “eaten” by the body’s immune response; medically, this reflects immune-mediated tissue injury rather than literal digestion.
Mechanistically, autoimmune gastritis is driven by loss of immune tolerance, with autoreactive T cells and autoantibodies against gastric targets. Two major clinical serologic phenotypes are recognized. Type 1 autoimmune gastritis is associated with antibodies against parietal cells and intrinsic factor, often leading to atrophic gastritis and eventual pernicious anemia. Type 2 autoimmune gastritis is associated with polyglandular autoimmune patterns and can involve other autoimmune diseases such as autoimmune thyroiditis, type 1 diabetes, or Addison disease. Over time, chronic inflammation results in glandular atrophy and intestinal metaplasia, increasing long-term risks for gastric neuroendocrine tumors and gastric adenocarcinoma. That risk stratification is part of why autoimmune gastritis requires ongoing monitoring rather than symptomatic, short-term management.
Clinically, autoimmune gastritis may present through consequences of malabsorption or anemia rather than direct pain. Iron deficiency anemia can occur because gastric acid supports iron absorption and because inflammatory changes may impair iron handling. Vitamin B12 deficiency, driven by intrinsic factor loss, can cause neurologic manifestations including paresthesias, gait instability, cognitive changes, and glossitis. Some patients have no obvious symptoms until laboratory abnormalities are detected during routine evaluation. Endoscopic findings can include atrophic mucosa and loss of rugal folds; histology confirms atrophy with lymphocytic infiltration and glandular destruction.
Diagnosis begins with targeted laboratory tests. A complete blood count may show microcytosis from iron deficiency or macrocytosis with hypersegmented neutrophils in B12 deficiency. Serum iron studies, ferritin, and transferrin saturation assess iron status. Serum vitamin B12 and methylmalonic acid can clarify functional B12 deficiency, particularly when B12 levels are borderline. Gastrin levels are often elevated due to reduced acid production, while pepsinogen markers may be altered. Serologic testing for anti–parietal cell antibodies and anti–intrinsic factor antibodies supports the autoimmune diagnosis; anti–intrinsic factor positivity is particularly specific for pernicious anemia. If autoimmune gastritis is suspected, clinicians also screen for associated autoimmune conditions.
Endoscopy with biopsy is central when alarm features exist or when laboratory findings indicate pernicious anemia or iron deficiency that is unexplained by other causes. Histopathology distinguishes autoimmune atrophic gastritis from other etiologies such as Helicobacter pylori–associated gastritis. H. pylori testing and eradication are important because infection can produce chronic inflammation and atrophy, and eradication reduces risk of complications. In autoimmune gastritis, treatment focuses on immune-driven sequelae and complication prevention.
Therapy is two-pronged: replace deficient nutrients and monitor for disease progression. Vitamin B12 replacement can be delivered via intramuscular injections or high-dose oral or sublingual formulations, depending on absorption and severity; ongoing levels and neurologic status guide dosing. Iron supplementation is provided orally or intravenously based on tolerance, severity, and response. Because the acid-producing capacity of the stomach may be reduced, some patients respond better to parenteral iron. Symptomatic dyspepsia may improve with acid suppression strategies in selected patients, but these do not reverse atrophy or intrinsic factor loss.
Because autoimmune gastritis increases malignancy risk, surveillance intervals are individualized based on histologic findings, extent of atrophy, presence of metaplasia, and co-factors such as family history. Patients with intestinal metaplasia or dysplasia require closer follow-up. Additional evaluation for associated endocrine autoimmunity is often warranted.
It is crucial to emphasize that the phrase “incurable” in public discussions often refers to no established therapy that fully eradicates the autoimmune process or restores destroyed parietal cells. However, clinical outcomes can be substantially improved through early recognition, correction of anemia, and long-term monitoring for complications. For individuals reporting symptoms suggestive of malabsorption, clinicians recommend not delaying evaluation—particularly when fatigue, anemia, neurologic symptoms, weight loss, persistent vomiting, or a family history of gastric malignancy is present.
Source: [@Real_Bob_Joyc]
ᶜᵒᵐᵐᵉⁿᵗᵃʳʸ Pastor Bob Joyce: The man who wants to live forever may have hit a speed bump. A fan of telling all about his longevity journey, biohacker Bryan Johnson recently shared on social media that he has an incurable autoimmune disease where his “stomach is eating itself.” And true to his biohacking. #breaking
— @Real_Bob_Joyc May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
